Cancer Research Clinical Trials
Search our team at AdventHealth Research Institute
-
NCT02215265
A Phase III Trial of Risk-Stratified, Reduced Intensity Adjuvant Treatment in Patients Undergoing Transoral Surgery for Human Papillomavarius (HPV)-Positive Oropharyngeal Cancer
This study is currently enrolling.Associated Conditions: Head and Neck CancerResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThis study aims to identify the best way of treating orpharyngeal cancer that are caused by HPV. At the moment, cancers caused by HPV are treated like any other cancer in the Head and Neck and the...
-
NCT03959085
A Phase 3 Randomized Trial of INotuzumab Ozogamicin (IND#: 133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
This study is currently enrolling.Associated Conditions: LeukemiaResearch Area: Clinical Cancer ResearchDisseminated B-Cell Lymphoblastic Lymphoma (B-LLy): The overall goal of this study is to determine the outcomes of subjects with disseminated B-LLy receiving High Risk B-cell Acute Lymphoblastic...
-
NCT02981628
A Phase 2 Study of INotuzumab Ozogamicin (NSC# 772518, IND #133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
This study is currently enrolling.Associated Conditions: LeukemiaResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThe overall goal of this study is to find out what effect, good and/or bad, the drug inotuzumab ozogamicin has on children and young adults with relapsed or refractory B-ALL.
-
NCT02402244
The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
This study is currently enrolling.Associated Conditions: Multiple Tumor TypesResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaWe are doing this study to find better ways to diagnose, treat and prevent cancers in children, adolescents and young adults. To do this, we need to learn more about cancers that happen to children...
-
NCT01515787
A Phase II/III of Neoadjuvant FOLFOX with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision (PROSPECT)
This study is currently enrolling.Associated Conditions: Colorectal CancerResearch Area: Clinical Cancer ResearchResearch Location: Orlando, Florida[$] [Abbreviated - Closed] The purpose of this study is to compare the effects, both good and bad, of the standard treatment of chemotherapy and radiation to chemotherapy using a combination regimen...
-
NCT06819007
A Phase 3, Open-label, Multicenter, Randomized Trial of Trastuzumab Deruxtecan with Bevacizumab Versus Bevacizumab Monotherapy as First-line Maintenance Therapy in HER2-Expressing Ovarian Cancer” GOG 3112/ DSI-T-DXd ENHERTU (DO-01); DESTINY-Ovarian01 (DO-01)] DS8201-772
This study is not currently enrolling.Associated Conditions: Ovarian, Fallopian, or Primary Peritoneum CancerResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThis study consists of two parts: Part 1 (safety run-in) and Part 2 (randomized part [like the flip of a coin]). The purpose of Part 1 is to learn more about the safety and tolerability of the...
-
NCT05929235
A Phase 1, First-in-Human, Dose-Escalation and Expansion Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma
This study is not currently enrolling.Associated Conditions: Multiple Tumor TypesResearch Area: Clinical Cancer ResearchResearch Location: Celebration, Florida -
NCT06456463
A Phase II multicenter open-label trial of tagraxofusp (Tag) in combination with venetoclax and azacitidine (Ven/Aza) in adults with previously untreated CD123+ acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy.
This study is not currently enrolling.Associated Conditions: LeukemiaResearch Area: Clinical Cancer Research -
NCT05858164
An open-label, phase 1, first-in-human, dose escalation and expansion study to evaluate the safety, tolerability, maximum tolerated or administered dose, pharmacokinetics, pharmacodynamics, and tumor response profile of the diacylglycerol kinase alpha inhibitor (DGKai) BAY 2862789 in participants with advanced solid tumors
This study is not currently enrolling.Associated Conditions: Metastatic Solid TumorsResearch Area: Clinical Cancer ResearchResearch Location: Celebration, FloridaThis study is being done to learn more about a new drug called BAY 2862789, an inhibitor of diacylglycerol kinase alpha (DGKα). BAY 2862789 is an immunotherapy drug that has been developed to activate...
-
NCT06188559
An Open-label, Multicenter, Phase 2 Dose Optimization and Expansion Study to Evaluate the Safety and Efficacy of BB-1701, an anti-human epidermal growth factor receptor 2 (anti-HER2) antibody-drug conjugate (ADC), in Previously Treated Subjects with HER2-positive or HER2-low Unresectable or Metastatic Breast Cancer
This study is not currently enrolling.Associated Conditions: Breast CancerResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThe purpose of this study is to determine if a new drug called BB-1701 is safe and effective in people who have HER2-positive or HER2-low, unresectable or metastatic breast cancer (MBC). There are two...
-
NCT05891171
A Phase 1, First-in-Human, Open-Label Study to Evaluate the Safety, Tolerability, PK, and Preliminary Anti-tumor Activity of the Novel Orally Available CDK2 Inhibitor NKT3447 in Adults With Advanced/Metastatic Solid Tumors
This study is not currently enrolling.Associated Conditions: Multiple Tumor TypesResearch Area: Clinical Cancer ResearchObjectives: Primary: Dose Escalation: To identify the recommended doses for expansion (RDEs) of NKT3447 in adult subjects with advanced/metastatic solid tumors Dose Expansion: To evaluate the...
-
NCT05904886
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (IMbrave152) (SKYSCRAPER-14)
This study is not currently enrolling.Associated Conditions: Liver CancerResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThe purpose of this study is to compare the effects, good or bad, of tiragolumab plus atezolizumab plus bevacizumab versus placebo plus atezolizumab plus bevacizumab on patients with HCC. In this...